Le Lézard
Classified in: Health, Business
Subjects: SVY, ACC

Deloitte's 10th Annual Accounting and Financial Reporting Update Offers Valuable Interpretive Guidance to Life Sciences Companies


NEW YORK, March 20, 2019 /PRNewswire/ --

What:

2019 edition?and 10th annual?Deloitte Life Sciences Accounting and Financial Reporting Update



Who:

  • Jeff Ellis, U.S. audit & assurance leader, life sciences and health care, life sciences industry professional practice director, audit & assurance partner, Deloitte & Touche LLP
  • Dennis Howell, senior consultation partner, accounting and reporting services, life sciences deputy industry professional practice director, audit & assurance partner, Deloitte & Touche LLP


When:

Available immediately



Audience:

Pharmaceutical manufacturers; biotechnology companies; medical device, diagnostic and medical equipment manufacturers; drug distributors; contract research organizations (CROs); contract manufacturing organizations (CMOs); and health technology companies.



Details:

Significant trends that could reshape the life sciences industry are unfolding in 2019, including the shift from treatment to wellness, pricing pressures, digital technology expansion, and increased use of real-world data and other advances in science. At the same time, finance and accounting professionals in the industry face complex issues and must exercise significant judgment in applying accounting rules and related interpretations affecting life sciences companies.

 

In the 10th anniversary of the publication's launch, Deloitte's Life Sciences accounting and financial reporting update?including interpretive guidance report provides comprehensive guidance on how finance professionals can address these industry issues and trends.

 

Large pharmaceutical companies, for example, can gain insights on how the new revenue recognition standard has been applied in practice, understand the emerging accounting for R&D funding arrangements and leases, and learn more about the upcoming changes to the PCAOB auditor's report.

 

Biotech and emerging growth companies, including those in the evolving health tech sector, will appreciate the completely new chapter on initial public offerings and the updated guidance on accounting for collaborative arrangements.

 

The 2019 Life Sciences accounting and financial reporting update offers in-depth insights on these and other emerging issues that can help life sciences financial professionals better navigate the accounting and reporting challenges they face.

As used in this document, "Deloitte" means Deloitte LLP. Please see  www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting. (PRNewsFoto/Deloitte)

About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90 percent of the Fortune 500 and more than 5,000 private and middle market companies. Our people work across the industry sectors that drive and shape today's marketplace to make an impact that matters ? delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthy society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. 

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Copyright © 2019 Deloitte Development LLC. All rights reserved.

 

SOURCE Deloitte


These press releases may also interest you

at 01:35
Regulatory News: Pernod Ricard (Paris:RI): Press Release ? Paris, 25 April 2024 This robust performance illustrates the strength of our diversified portfolio of premium international spirits and our broad-based geographic footprint covering...

at 01:30
Happiest Minds Technologies Limited (NSE: HAPPSTMNDS), a 'Born Digital. Born Agile', Mindful IT Company, today announced it signed definitive agreements to acquire 100% of the equity share capital of PureSoftware Technologies Private Limited...

at 01:21
Aker Solutions has delivered strong revenue growth and improved profitability in the first quarter of 2024 compared to the same period last year. With a solid backlog and high tendering activity, the company is well positioned for future profitable...

at 01:18
First Quarter Highlights            HMH delivered an EBITDA (adj.) of USD 33 million in quarter, about 75% increase year-over-year driven by higher aftermarket activityNES Fircroft delivered 17% increase in EBITDA and 12% revenue growth...

at 01:17
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 01:16
PERIOD 1 JANUARY - 31 MARCH 2024 Net sales decreased by 7% (same in local currencies) and amounted to SEK 1,995.2 (2,135.5) million. Acquired business contributed 1%.Operating result amounted to SEK 185.5 (313.5) million.Result for the period...



News published on and distributed by: